The CD4 count has been reported to decline less rapidly in HIV-infected haemophiliacs treated with monoclonally purified factor VIII concentrates than in those using intermediate-purity concentrates. No survival advantage has been demonstrated for this effect, and it is unclear whether this effect occurs with all high-purity concentrates. Two cohorts of patients with severe haemophilia A and HIV treated with either ion-exchange-purified or monoclonally-purified concentrates were compared. The CD4 count, survival, AIDS-defining illnesses, CDC category and anti-retroviral therapy were recorded at 6-monthly intervals for 3 years following the change from intermediate to high-purity factor VIII. 116 patients were recruited, 37 of whom were treated with an ion-exchange purified factor VIII concentrate at three centres, mean (SD) age 31.1 (12.2) years, and 79 were treated with monoclonally purified factor VIII concentrate at two centres, mean (SD) age 29.8 (11.2) years. At the start of the study the median CD4 count was (monoclonal v ion-exchange) 0.30 v 0.16 × 10⁹/l. The CD4 count declined in both arms to a median of (monoclonal v ion-exchange) 0.16 v 0.08 × 10⁹/l at the final visit. Analysis of the (CD4 count)^1/2 over time, using a random coefficients model, found that the mean (SE) rates of decline were not statistically significantly different in the two treatment groups (monoclonal v ion exchange: −0.050 (0.008) v−0.034 (0.011) (CD4 count)^1/2 per year, P = 0.24). No statistically significant difference in survival (log-rank test: P = 0.33) was found. There was no difference in the proportion of individuals experiencing one or more AIDS-defining illnesses (P = 0.32) or in the proportion progressing to CDC category IV (P = 0.28) during the study. The CD4 count declined during the study at a rate similar to that previously reported in patients treated with intermediate-purity factor VIII concentrate, and there was no evidence of any difference between the two treatment groups.

References

1 Berntorp, E. (1994) Impact of replacement therapy on the evolution of HIV infection in haemophiliacs. Thrombosis and Haemostasis, 71, 678 683.
10.1055/s-0038-1642504
CAS PubMed Web of Science® Google Scholar
2 Concorde Coordinating Committee (1994) Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet, 343, 871 881.
10.1016/S0140-6736(94)90006-X
PubMed Web of Science® Google Scholar
3 Darby, S.C., Rizza, C.R., Doll, R., Spooner, R.J.D., Stratton, I.M., Thakrar, J. (1989) Incidence of AIDS and excess of mortality associated with HIV in haemophiliacs in the United Kingdom: report on behalf of the directors of haemophilia centres in the United Kingdom. British Medical Journal, 298, 1064 1068.
10.1136/bmj.298.6680.1064
CAS PubMed Web of Science® Google Scholar
4 De Biasi, R., Rocino, A., Miraglia, E., Mastrullo, L., Quirino, A.A. (1991) The impact of very high purity factor VIII concentrate on the immune system of HIV infected hemophiliacs: a randomised prospective, 2 year comparison with intermediate purity concentrate. Blood, 78, 1919 1923.
CAS PubMed Web of Science® Google Scholar
5 Eyster, M.E., Gail, M.H., Ballard, J.O., Al-Mondhiry, H., Goedert, J.J. (1987) Natural history of human immunodeficiency virus. Infections in haemophiliacs: effects of T-cell subsets, platelet counts and age. Annals of Internal Medicine, 107, 1 6.
10.7326/0003-4819-107-1-1
PubMed Web of Science® Google Scholar
6 Fischl, M.A., Richman, D.R., Hansen, N., Collier, A.C., Carey, J.T., Para, M.F. (1990) The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type I (HIV) infection: a double-blind, placebo-controlled trial. Annals of Internal Medicine, 112, 723 737.
10.7326/0003-4819-112-10-727
PubMed Web of Science® Google Scholar
7 Goldsmith, J.M., Deutche, J., Tang, M., Green, D. (1991) CD4 cells in HIV-1 infected haemophiliacs: effect of factor VIII concentrates. Thrombosis and Haemostasis, 66, 415 419.
10.1055/s-0038-1646430
CAS PubMed Web of Science® Google Scholar
8 Hay, C.R.M. & McEvoy, P. (1992) Purity of factor VIII concentrates. Lancet, 339, 1613.
10.1016/0140-6736(92)91879-D
CAS PubMed Web of Science® Google Scholar
9 Hilgartner, M.W., Buckley, J.J., Operskalski, E.A., Pike, M.C., Mosley, J.W., for the Transfusion Safety Study Group (1993) Purity of factor VIII concentrates and serial CD4 counts. Lancet, 341, 1373 1374.
10.1016/0140-6736(93)90943-B
CAS PubMed Web of Science® Google Scholar
10 Lee, C.A., Phillips, A., Elford, J., Miller, E.J., Bofill, M., Griffiths, P.D., Kernoff, P.B.A. (1989) The natural history of human immunodeficiency virus in a haemophilic cohort. British Journal of Haematology, 73, 228 234.
10.1111/j.1365-2141.1989.tb00257.x
PubMed Web of Science® Google Scholar
11 Ludlam, C.A., Tucker, J., Steel, C.M. (1985) Human lymphotropic virus type III (HTLV III) infection in seronegative patients after transfusion of factor VIII. Lancet, ii, 233 236.
10.1016/S0140-6736(85)90288-0
CAS Google Scholar
12 Mannucci, P.M., Gringeri, A., De Biasi, R., Baudo, F., Morfini, M., Ciavarella, N. (1992) Immune status of asymptomatic HIV-infected haemophiliacs: randomised comparison of treatment with high-purity with intermediate-purity factor VIII concentrate. Thrombosis and Haemostasis, 67, 310 313.
10.1055/s-0038-1648438
CAS PubMed Web of Science® Google Scholar
13 Menitove, J.E., Aster, R.H., Casper, J.T. (1983) T-lymphocyte sub-populations in patients with classical hemophilia treated with cryoprecipitate and lyophylised concentrates. New England Journal of Medicine, 308, 83 86.
10.1056/NEJM198301133080206
PubMed Web of Science® Google Scholar
14 Morfini, M., Radfanelli, D., Filimberti, E., Cinotti, S., Piazza, E., Longo, G., Ferrini, P.R. (1989) Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates. Thrombosis Research, 56, 169 178.
10.1016/0049-3848(89)90159-X
CAS PubMed Web of Science® Google Scholar
15 Sabin, C., Pasi, J., Phillips, A., Elford, J., Janossy, G., Lee, C.A. (1994) CD4⁺ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients. Thrombosis and Haemostasis, 72, 214 217.
10.1055/s-0038-1648841
CAS PubMed Web of Science® Google Scholar
16 Seremetis, S., Aledort, L., Allaine, J., Bona, R., Bray, C., Eyster, E., Brettler, D., Kessler, C., Lusher, J., Rickles, S., Sacks, H. (1993) A comparison of immune function in HIV seropositive haemophilic patients randomised to treatment with intermediate purity and monoclonally immunopurified factor VIII concentrate. Lancet, 342, 700 703.
10.1016/0140-6736(93)91706-R
PubMed Web of Science® Google Scholar
17 Steel, C.M., Ludlam, C.A., Beatson, D., Peutherer, J.F., Cuthbert, R.J.G., Simmonds, P., Morrison, H., Jones, M. (1988) HLA-haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet, i, 1185 1188.
10.1016/S0140-6736(88)92009-0
CAS Google Scholar
18 U.K. Haemophilia Centre Directors Organisation (UKHCDO) (1992) Recommendations on choice of therapeutic products for the treatment of patients with haemophilia A, haemophilia B and von Willebrand's disease. Blood Coagulation and Fibrinolysis, 3, 205 214.
10.1097/00001721-199204000-00011
PubMed Web of Science® Google Scholar
19 U.K. Haemophilia Centre Directors Organisation (UKHCDO) (1997) Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. Haemophilia, 3, 63 77.
10.1046/j.1365-2516.1997.00073.x
PubMed Web of Science® Google Scholar
20 Volberding, P.A., Lagakos, S.W., Koch, M.A., Pettinelli, C., Myers, M.W., Booth, D.K. (1990) Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4 positive cells per cubic milimeter. New England Journal of Medicine, 322, 941 949.
10.1056/NEJM199004053221401
PubMed Web of Science® Google Scholar
21 Wadhwa, M., Dilger, P., Tubbs, J., Barrowcliffe, T., Mahon, B., Thorpe, R. (1992) Mechanisms of inhibition of T-cell IL-2 secretion by factor VIII concentrates. British Journal of Haematology, 82, 578 583.
10.1111/j.1365-2141.1992.tb06470.x
Web of Science® Google Scholar
22 Wadhwa, M., Dilger, P., Tubbs, J., Mire-Sluis, A., Barrowcliffe, T., Thorpe, R. (1994) Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood, 84, 2021 2030.
10.1182/blood.V84.6.2021.2021
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume101, Issue4

June 1998

Pages 632-637

The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison

Abstract

References

Citing Literature

References

Related

Information